GlassScriptPhysician profile
Taylor Lee Simon
NPI 1457085979
$5,089.13
in general payments reported to CMS, 2019-2025
32 companies · $757 in 2025
The $757 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,889 · 2024: $2,443 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,777 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.89 |
| Education | $312.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,101.41 | 2023-2025 | Enhertu, Lynparza, Datroway |
| Daiichi Sankyo INC. | $579.03 | 2023-2025 | Enhertu |
| Incyte Corporation | $348.05 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $309.22 | 2024-2025 | |
| Pfizer INC. | $278.65 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $258.75 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $252.19 | 2023-2024 | Yonsa |
| Gilead Sciences, INC. | $212.70 | 2023 | Trodelvy |
| Janssen Biotech, INC. | $207.66 | 2023-2024 | Rybrevant, Tecvayli, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $190.84 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $188.53 | 2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $146.03 | 2023-2025 | |
| Lilly USA, LLC | $143.11 | 2024-2025 | Jaypirca, Verzenio |
| Menarini Silicon Biosystems, INC. | $108.60 | 2024 | |
| Genmab U.S., INC. | $96.47 | 2024-2025 | Epkinly |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $68.44 | 2024-2025 | |
| Genentech USA, INC. | $68.13 | 2023-2025 | Itovebi, Venclexta, Lunsumio |
| Taiho Oncology, INC. | $53.54 | 2023-2024 | |
| Eisai INC. | $52.88 | 2023-2025 | |
| Astellas Pharma US INC | $52.70 | 2023 | Padcev, Xospata |
| Jazz Pharmaceuticals INC. | $48.53 | 2025 | |
| Sumitomo Pharma America, INC. | $45.53 | 2023-2024 | Orgovyx |
| Stemline Therapeutics INC. | $41.67 | 2023 | Orserdu |
| Telix Pharmaceuticals | $38.55 | 2025 | Illuccix |
| Agios Pharmaceuticals, INC. | $30.44 | 2024 | Pyrukynd |
| Tersera Therapeutics LLC | $28.00 | 2023 | Zoladex |
| Emd Serono, INC. | $26.67 | 2023 | Bavencio |
| Merck Sharp & Dohme LLC | $24.93 | 2024 | Lynparza, Keytruda |
| Seagen INC. | $23.98 | 2023 | Adcetris |
| Rigel Pharmaceuticals, INC. | $23.33 | 2023 | Tavalisse, Rezlidhia |
| Cti Biopharma Corp. | $22.00 | 2023 | Vonjo |
| Morphosys, US INC. | $18.57 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.